Mostrar el registro sencillo del ítem

dc.contributor.authorRiquelme, Ismael
dc.contributor.authorPérez-Moreno, Pablo
dc.contributor.authorLetelier, Pablo
dc.contributor.authorBrebi, Priscilla
dc.contributor.authorRoa, Juan Carlos
dc.date.accessioned2024-04-10T06:15:16Z
dc.date.available2024-04-10T06:15:16Z
dc.date.issued2022
dc.identifier10.3390/cancers14010202
dc.identifier.issn20726694
dc.identifier.urihttps://hdl.handle.net/20.500.12728/10934
dc.description.abstractGastrointestinal (GI) cancers produce ~3.4 million related deaths worldwide, comprising 35% of all cancer-related deaths. The high mortality among GI cancers is due to late diagnosis, the presence of metastasis and drug resistance development. Additionally, current clinical markers do not adequately guide patient management, thereby new and more reliable biomarkers and therapeutic targets are still needed for these diseases. RNA-seq technology has allowed the discovery of new types of RNA transcripts including PIWI-interacting RNAs (piRNAs), which have particular characteristics that enable these molecules to act via diverse molecular mechanisms for regulating gene expression. Cumulative evidence has described the potential role of piRNAs in the development of several tumor types as a likely explanation for certain genomic abnormalities and signaling pathways’ deregulations observed in cancer. In addition, these piRNAs might be also proposed as promising diagnostic or prognostic biomarkers or as potential therapeutic targets in malignancies. This review describes important topics about piRNAs including their molecular characteristics, biosynthesis processes, gene expression silencing mechanisms, and the manner in which these transcripts have been studied in samples and cell lines of GI cancers to elucidate their implications in these diseases. Moreover, this article discusses the potential clinical usefulness of piRNAs as biomarkers and therapeutic targets in GI cancers. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.es_ES
dc.description.sponsorshipDIUA, (226-2021); DIUFRO, (DI20-0128); Universidad Autónoma de Chile; Vicerrectoría Investigación de Universidad Católica de Temuco, (FIAII 2021-01); Horizon 2020 Framework Programme, H2020, (825510); European Research Council, ERC; Fondo Nacional de Desarrollo Científico y Tecnológico, FONDECYT, (1210440, 1221345, 3210237); Universidad de La Frontera, UFRO; Fondo de Fomento al Desarrollo Científico y Tecnológico, FONDEF, (ID21I10027); Instituto Milenio en Inmunología e Inmunoterapia, MIII, (ICN2021_045)es_ES
dc.language.isoenes_ES
dc.publisherMDPIes_ES
dc.subjectDiagnostic biomarkerses_ES
dc.subjectGastrointestinal cancers (GI cancers)es_ES
dc.subjectPIWI-interacting RNAs (piRNAs)es_ES
dc.subjectPrognostic biomarkerses_ES
dc.subjectTherapeutic targetses_ES
dc.titleThe emerging role of piwi-interacting rnas (Pirnas) in gastrointestinal cancers: An updated perspectivees_ES
dc.typeArticlees_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem